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Edited by Jesus AvilaAbstract Accumulation of hyperphosphorylated Tau is associ-
ated with a number of neurodegenerative diseases collectively
known as tauopathies. Diﬀerences in clinical and cognitive pro-
ﬁles among them suggest diﬀerential sensitivity of neuronal pop-
ulations to Tau levels, phosphorylation and mutations. We used
tissue speciﬁc expression of wild type and mutant human tau
transgenes to demonstrate diﬀerential phosphorylation and sta-
bility in a cell type-speciﬁc manner, which includes diﬀerent neu-
ronal types and does not correlate with the level of accumulated
protein. Rather, they likely reﬂect the spatial distribution or reg-
ulation of Tau-targeting kinases and phosphatases.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Drosophila1. Introduction
Tau is a microtubule binding protein, preferentially distrib-
uted in the axons of the central (CNS) and some neurons of
the peripheral (PNS) nervous system [1]. In humans, six Tau iso-
forms arise via tissue and temporally regulated alternative splic-
ing that yield proteins with 3 or 4 microtubule binding repeats
(3R, 4R) and diﬀerent amino-terminal sequences (0–2N) [2].
Tau is extensively phosphorylated either constitutively [3,4],
or facilitated (primed) at particular sites, by prior phosphoryla-
tion [5]. Tauopathies are a diverse group of neurodegenerative
dementias characterized by intraneuronal aggregation of hyper-
phosphorylated Tau [3,4,6]. Mutations in the single tau gene
cause hereditary Frontotemporal Dementia with Parkinsonism
linked to chromosome 17 (FTDP-17) [4]. In contrast, accumu-
lation of hyperphosphorylated normal Tau yields intracellular
aggregates varying in regional distribution and morphology
(Neuroﬁbrilar Tangles (NFTs) and Paired Helical Filaments
(PHFs)) that characterize Alzheimer’s (AD), Pick’s Disease
and other tauopathies [2,3]. Tauopathies are diﬀerentiated by
their unique clinical and cognitive proﬁles, likely reﬂective of
the regional distribution of CNS pathology [2,7]. This is indic-
ative of the diﬀerential sensitivity of particular neuronal groups
to Tau levels, phosphorylation and mutations [6]. Cell type-spe-
ciﬁc aggregate formation is a probable consequence of diﬀeren-
tial distribution of kinases and phosphatases that target Tau
[5,8,9]. Although, the human data indicate that all CNS and*Corresponding author. Fax: +30 210 965 6563.
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doi:10.1016/j.febslet.2006.07.045PNS neurons are not equally susceptible to pathogenesis and
this diﬀerential sensitivity is important for diagnosis [2,7,10],
it tends to be overlooked in tauopathy models.
The genetic versatility of Drosophila has advanced our
understanding of Tau toxicity, age-dependent neurodegenera-
tion [11–14] and learning and memory and axonal transport
defects [15,16]. In ﬂies, NFT formation required Tau co-
expression with Tau-targeting kinases such as GSK-3b
[12,17,18]. Even then, the degree of aggregate formation and
their characteristics appeared to vary in a cell type-dependent
manner [11,12,17]. Here, we address the hypothesis that Tau
proteins are diﬀerentially processed in particular Drosophila
tissues and neuronal populations. Because hyperphosphoryla-
tion is the main characteristic of pathological Tau, we focused
on phosphorylation patterns in the tissues targeted in most
Drosophila models, the retina and the nervous system.2. Materials and methods
2.1. Drosophila culture and strains
Drosophila were cultured in soy ﬂour and CaCl2-supplemented
sugar–wheat ﬂour food. Gal4 driver lines were: the pan-neural driver
ELAV, the retina-speciﬁc GMR, the mushroom body driver c772
[15] and the larval motor neuron driver D42-Gal4 [19]. UAS-htauWT,
UAS-htauR406W, UAS-htauV337M transgenics [11] were provided by
M. Feany, while the UAS-htauR406WS2A [17] was obtained from B.
Lu and UAS-btau from Ito [20].
2.2. Western blotting and antibodies
Tissues from 2 to 3-day-old adult females and 3rd instar larvae were
homogenized in 1· Laemmli buﬀer (50 mM Tris pH 6.8, 100 mM
DTT, 5% 2-mercaptoethanol, 2% SDS, 10% glycerol and 0.01% bro-
mophenol blue). The lysates were heated for 10 min at 95 C, centri-
fuged at 8000 · g for 5 min and separated in SDS–acrylamide gels.
Because of varying aﬃnities of anti-Tau antibodies and eﬃciency of
Gal4 drivers, the amount of extract loaded per lane for best resolution
was determined experimentally for each antibody. Proteins were trans-
ferred to PVDF membranes and probed with the monoclonal antibod-
ies: anti-Tau (TOTAL) (Zymed laboratories) at 1:1000, AT100 (Pierce
Endogen) at 1:250 and the polyclonal antibodies pS262 (Biosource) at
1:500 and pS396 (Biosource) at 1:2000. Monoclonal antibodies AT8
(used at 1:200), AT180 (used at 1:200) and TAU 1 (used at 1:2000)
were kindly provided by A. Mudher. To normalize for sample loading,
the membranes were concurrently probed with an anti-syntaxin mono-
clonal antibody (8C3, Developmental Studies Hybridoma Bank) at a 1/
2000. Bovine Tau was detected with a monoclonal antibody (Sigma),
not cross-reacting with human Tau at 1:1000. A rabbit polyclonal
anti-Beta-Galactosidase antibody (Rockland) was used at 1:1000. Pro-
teins were visualized with chemiluminescence.
2.3. In vitro dephosphorylation
Heads were homogenized in RIPA (137 mM NaCl, 20 mM Tris pH
8.0, 10% glycerol, 0.1% SDS and 0.1% sodium deoxycholate) supple-
mented with protease inhibitors (Sigma). Twenty micrograms of total
protein was treated with 400 U k-phosphatase (New England Biolabs)blished by Elsevier B.V. All rights reserved.
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third of each sample was resolved by SDS–PAGE and subjected to
western blot analysis.Fig. 1. Distinct patterns of Tau accumulation in the retina and neurons
reﬂect phosphorylation diﬀerences. (A) A representative semi-quanti-
tative Western blot of head lysates from ﬂies accumulating WT and
mutant Tau in the retina (GMR-GAL4) and nervous system (ELAV-
GAL4), probed with an antibody that recognizes all human Tau species
(TOTAL antibody). Three heads were loaded per lane. Drosophila anti-
syntaxin antibody (SYN) was used to monitor loading. (B) Bovine Tau
(BTauWT) and, b-galactosidase (bgal) were similarly expressed in the
retina and neurons with GMR and ELAV. Equal amounts of protein
were loaded per lane. (C) Equal amount (6.5 lg) of head lysates from
animals accumulating WT and mutant Tau proteins under ELAV and
GMR-Gal4 were subjected to in vitro dephoshorylation by k-phospha-
tase (k-phos, +). The reactions were analyzed byWestern blotting using
the TOTAL Tau antibody (TAU) alongside with equal amount of head
lysates without phosphatase (), or untreated lysates (L). Equivalent
amounts of protein were used per lane as probing with SYN veriﬁed,
while phosphate removal from SYN in treated samples (+) yielding
smaller species ascertained phosphatase activity.3. Results
3.1. Diﬀerential accumulation of human tau transgenic proteins
in the Drosophila eye and brain
We used htauWT transgenics because the wild type (WT)
Tau accumulates in heritable and sporadic AD and the
FTDP-17-linked mutations R406W and V337M [11], because
FTDP-17 has distinct distribution and symptoms from AD
[4,21]. Finally, the triple mutant R406WS2A bears mutations
in sites reported essential for primed Tau phosphorylation in
R7 photoreceptors [17] and was used to probe utilization of
these sites in other cell types. To facilitate the analysis and
inter-transgene comparisons, all transgenic proteins were of
the 1N4R isoform. We compared tissue speciﬁc Tau accumula-
tion using the UAS/Gal4 system [22] and the GMR and ELAV
drivers because they are commonly used in Drosophila Tauop-
athy models [13,14,23] and both direct Tau accumulation in tis-
sues, where the Drosophila ortholog is found [24]. GMR is
expressed in neurons of the retina including photoreceptors,
but also in non-neuronal structural and supporting cells [25].
ELAV directs expression in all CNS and PNS neurons [26].
WT and mutant Tau in the retina appeared as a higher than
the predicted size multi-species broad band (Fig. 1A). Similar
amounts of WT and V337M accumulated, while R406WS2A
appeared elevated and R406W relatively reduced. In contrast,
Tau accumulating in neurons appeared as a single species
slightly larger than the biggest species under GMR
(Fig. 1A). Considering the large number of neurons accumu-
lating Tau in heads, the protein levels suggest that ELAV is
a weaker driver than GMR. Strikingly, the R406WS2A protein
which exhibited the highest accumulation under GMR was
nearly absent under ELAV, indicating that the S262 and
S356 to A mutations [17] render it less stable in neurons.
The multi-band protein accumulation under GMR was also
exhibited by a bovine Tau, which appeared as a single band
in neurons. In contrast, like green ﬂuorescent protein (GFP)
and other exogenous proteins (not shown), b-galactosidase
accumulated as a single species under both drivers (Fig. 1B).
These data indicate that the distinct protein proﬁles do not re-
ﬂect inherent diﬀerences in processing or stability of all non-
Drosophila proteins in the two tissues, but rather are speciﬁc
to Tau.
The multiple species in the retina could reﬂect partially phos-
phorylated or otherwise modiﬁed proteins. Alternatively, they
could be degradation or incomplete translation products. To
resolve this, Tau proteins accumulating in the retina or neu-
rons were subjected to in vitro de-phosphorylation with k-
phosphatase. Tau in the nervous system and the largest species
in the retina exhibited an apparent molecular size of 60–62 kD.
De-phosphorylation yielded a single band of 48–50 kD, irre-
spective of whether WT or mutant Tau accumulated in the
retina or neurons (Fig. 1C). Smaller than full length de-phos-
phorylated proteins were not observed, even upon over-expo-
sure of the blots or probing with additional anti-Tau
antibodies (not shown). These results are consistent with the
notion that the multiple Tau species in the retina were not
products of degradation or abortive translation. Hence, whileTau is maximally phosphorylated in neurons, phosphorylation
in the retina appeared incomplete, yielding multiple bands.
Note that although equivalent amounts were used, incubation
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This was apparent for proteins accumulating in the retina and
to a lesser degree with Tau in neurons. This suggested that
partially phosphorylated Tau may be more vulnerable to
endogenous proteases than maximally phosphorylated, or de-
phosphorylated protein. In the nervous system, this may
account for the reduced stability of the R406WS2A protein.Fig. 2. Survey of key phosphorylation sites on Tau proteins in the
retina and nervous system. (A) Western blots from head lysates of
animals accumulating the indicated WT and mutant proteins in the
retina and brain were probed with the TOTAL Tau antibody and
phospho-speciﬁc antibodies to investigate phosphorylation at sites
progressively from amino to carboxy-terminus: AT8, AT100, AT180,
pS262 and pS396. TAU1 was used to detect non-phosphorylated Tau
at the positions recognized by the AT8 phospho-antibody. SYN was
used to ascertain equivalent loading (lower band in all panels). To
normalize for the diﬀerent aﬃnities of the anti-Tau antibodies, the
number of female heads used per lane was adjusted as follows: anti-
total Tau, 3 heads/lane; AT-8, 1head/lane; AT100, 7 heads/lane;
AT180, 1 head/lane; pS262, 7 heads/lane; pS396, 1 head/lane; TAU1, 1
head/lane. (B) htauWT expressing ﬂies under the GMR or ELAV
drivers were raised at the indicated temperatures to manipulate the
amount of transgenic protein produced. The total amount of Tau
(TOTAL) and that phosphorylated at positions 212/214 (AT100) was
assessed in the corresponding head lysates (3 heads/lane for anti-
TOTAL Tau and 7 heads/lane for AT100).3.2. Distinct phosphorylation of Tau in the retina and the
nervous system
We used phospho-speciﬁc antibodies to uncover diﬀerentially
phosphorylated epitopes in the retina and nervous system
(Fig. 2A). Because phosphorylation at S202/T205, is frequently
associated with AD, its status was probed with antibody AT8
[3] and was found occupied both in the retina and the nervous
system. This site is targeted by cdk-5 and GSK-3b, but was re-
ported to require priming phosphorylation at S262 and S356 by
the kinase Par1 in R7 photoreceptor neurons [17]. Signiﬁcantly,
although reduced in comparison to WT, the R406WS2A pro-
tein lacking these Par1 sites appeared phosphorylated in the ret-
ina. Furthermore, despite the much reduced R406WS2A
accumulation in neurons, its phosphorylation on S202/T205
was clearly not eliminated indicating that it occurred in non-
R7 cells of the retina and CNS neurons.
These results were conﬁrmed using the TAU1 antibody,
which recognizes unphosphorylated S202/T205. As expected,
the majority of R406WS2A protein in the retina appeared
unphosphorylated at that site. In contrast, low signal was de-
tected onR406WS2A in the nervous system, conﬁrming that de-
spite its low abundance most of the protein is phosphorylated
on S202/T205. In addition, multiple species were identiﬁed by
this antibody when Tau accumulated in the retina, indicating
that S202/T205 remained unphosphorylated in a large fraction
of WT and mutant proteins. In neurons, the antibody recog-
nized an apparent single species lacking S202/T205 phosphory-
lation onWT and mutant proteins. This indicates that the band
detected with the TOTAL antibody contains at least two species
diﬀering in S202/T205 phosphorylation, a size diﬀerence too
small to resolve in our gels.
A major phosphorylation diﬀerence was uncovered at T212/
S214, which is recognized by the AT100 antibody and targeted
by GSK-3b [3]. Minimal phosphorylation was detected on Tau
accumulating in the retina and was absent from R406WS2A
(veriﬁed by longer exposure of the blots – not shown). The
low level of T212/S214 phosphorylation on WT and mutant
proteins in the retina likely occurred in photoreceptor neurons
because immunostaining with AT100 has been reported to re-
veal a diﬀuse signal for WT Tau in these cells [13]. In contrast,
T212/S214 appeared phosphorylated on Tau accumulating in
neurons, except for R406WS2A. This is highly signiﬁcant, be-
cause T212/S214 phosphorylation constitutes a tauopathy-spe-
ciﬁc epitope and is linked to the presence of NFTs, or the
potential to form them [8,12]. The prominent T212/S214 phos-
phorylation on Tau in neurons suggested that GSK-3b is either
distributed preferentially, or the phosphorylation is more sta-
ble in neurons compared to cells of the retina.
Phosphorylation at T231/S235 by GSK-3b [27] has been re-
ported to aﬀect microtubule binding [2] and this epitope, often
associated with tauopathies is recognized by the AT180 anti-
body [3]. T231/S235 was strongly phosphorylated on Tau
accumulating in the retina and the nervous system. In contrast,phosphorylation at this site on R406WS2A was barely detect-
able in the retina and absent in the nervous system. These re-
sults are in agreement with the proposed requirement for
priming by Par1 for subsequent GSK-3b-mediated phosphor-
ylation at T231/S235 [17]. Indeed, phosphorylation at the
S262 Par-1 site [17], was eliminated on R406WS2A, but not
other Tau proteins both in the retina and the nervous system
as expected. An additional unprimed GSK-3b or cdk5 phos-
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S396 [27] and is associated with tauopathies and PHF forma-
tion [2,6]. S396 was phosphorylated on all Tau proteins accu-
mulating in the retina and neurons. However, given the level of
R406WS2A in the retina, S396 phosphorylation appeared
mildly reduced compared to that on WT. In contrast, even
though much reduced in neurons, all R406WS2A appeared
phosphorylated at this site.
Collectively, the results indicate diﬀerential phosphorylation
on a number of sites depending on whether Tau accumulates in
the retina or the nervous system and a large fraction of Tau re-
mains partially phosphorylated in the eye. These diﬀerences
could arise because of the increased level of Tau accumulation
under GMR, or cell type-speciﬁc diﬀerences in the distribution
of kinases and phosphatases that target it. Manipulating trans-
gene expression by raising animals at diﬀerent temperatures
[15,28] did not alter the pattern of Tau accumulation, or
T212/S214 phosphorylation (Fig. 2B). Therefore, phosphory-
lation diﬀerences do not result from overwhelming responsible
kinases with excess transgenic proteins. Rather, the results are
consistent with limited distribution of Tau-targeting kinases,
or diﬀerential regulation of their activities in the tissues and
cell types under investigation.
3.3. Neuronal type speciﬁc post-translational processing of Tau
To explore the possibility that human Tau is processed dif-
ferently in various populations of Drosophila neurons, we ex-
pressed WT Tau in the mushroom bodies (MBs) using the c772
driver [15,29]. The MBs, are comprised of approximately 5000
CNS neurons essential for olfactory learning and memory [30].
Tau in the MBs accumulated in a proﬁle identical to that under
ELAV and was highly phosphorylated at S202/T205 (AT8)
and T212/S214 (AT100) (Fig. 3). Longer exposure of the blots
did not reveal additional bands, and the pattern did not change
if ﬂies were raised at 29 C (not shown). In contrast, a smaller
Tau species accumulated in larval motor neurons [16],
which lacked phosphorylation at S202/T205 and T212/S214
(Fig. 3). However, this species contained other modiﬁcations
since it appeared larger than the 42 kD predicted size of Tau.
As expected, the smaller protein was also present in larvae
expressing Tau pan-neuronally (ELAV). A larger species, ab-
sent from larvae expressing Tau in motor neurons, thus accu-
mulating in all other neuronal types, appeared similar in size to
that found in adult CNS. In agreement, S202/T205 and T212/
S214 were occupied only on the larger species accumulating inFig. 3. Speciﬁc processing of Tau in diﬀerent neuronal populations.
Diﬀerences in phosphorylation pattern of WT Tau accumulating in
adult mushroom bodies (c772, 7 heads/lane), in the eye (GMR, 2 heads
per lane), the entire nervous system in adults (ELAV, 2 heads/lane) and
larvae (1 larva/lane) and larval motor neurons (D42, 1 larva/lane).non-motor larval neuronal populations (Fig. 3). Therefore,
Tau accumulating in these two diﬀerent types of larval neurons
appears to be processed diﬀerently, likely a reﬂection of the ki-
nases and phosphatases targeting this protein present in each
cell type. In agreement with this interpretation, co-expression
of GSK-3b in larval motor neurons has been shown to increase
Tau phosphorylation [16].
These results demonstrate that cell type-speciﬁc phosphory-
lation on particular sites and possibly other post-translational
modiﬁcations on human Tau occur diﬀerentially in diﬀerent
Drosophila neuronal types, potentially mirroring the complex-
ity of Tau post-translational processing in vertebrates [1,2].4. Discussion
Tauopathy models must diﬀerentiate the eﬀects of WT and
mutant Tau proteins and take into consideration their cell
type-speciﬁcity. Comparison of phosphorylations on WT and
mutant Tau proteins did not reveal signiﬁcant interallelic dif-
ferences for proteins accumulating in the retina, or the nervous
system, except for the R406WS2A mutant [17]. Importantly
however, we observed signiﬁcant tissue speciﬁc diﬀerences in
Tau phosphorylation, attributable at least in part to distinct
utilization of phosphorylation sites in the retina and neurons.
The two most prominent diﬀerences uncovered were underuti-
lization of S202/T205 and T212/S214 in the retina, and total
lack of these modiﬁcations in larval motor neurons in compar-
ison to that in the CNS. Both sites were occupied in MB neu-
rons, where accumulation of the WT protein was linked to
learning and memory deﬁcits [15]. Because S202/T205 and
T212/S214 phosphorylation was apparently also absent from
protein accumulating speciﬁcally in R7 photoreceptor neurons
[17], collectively these results suggest that this likely character-
izes Tau accumulating in the PNS. Therefore, Drosophila CNS
processes Tau similar to vertebrate neurons susceptible to AD
[2,4] and is processed diﬀerently in the PNS, in agreement with
human data [2]. Because in the retina and larval motor neurons
S202/T205 and T212/S214 sites were unoccupied, these tissues
are not optimal AD models since the disease is characterized
by phosphorylation of these sites, but rather tauopathies not
requiring these speciﬁc modiﬁcations. In fact, larval motor
neurons served to model Tau-dependent impairments in anter-
ograde transport [16,31], a condition common to multiple tau-
opathies possibly preceding aggregate formation. Both S202/
T205 and T212/S214 sites are targeted by GSK3b, a kinase
found to accumulate strongly in the adult CNS and retinal
cone and pigment cells, but not appreciably in photoreceptor
neurons (Supplementary Fig. 1). Therefore, reduced S202/
T205 and T212/S214 phosphorylation in cone and pigment
cells expressing Tau under GMR, is a likely consequence of
limited GSK3b activity, access to these sites, or increased
activity of a speciﬁc phosphatase.
Surprisingly, the priming phosphorylation at S262 and S356
by Par1 in R7 photoreceptors [17] was not essential for S202/
T205 occupation in other neurons. These results indicate that
Par1 phosphorylation is not a requisite priming modiﬁca-
tion in all neuronal types, or it has an allele speciﬁc eﬀect in
diﬀerent tissues. In support of the later notion, although
over-expressing Par1 in R7 cells enhanced R406W-mediated
neurodegeneration [17], it appeared to suppress V337M-
mediated degeneration in the retina [18]. Another surprising
4606 S. Grammenoudi et al. / FEBS Letters 580 (2006) 4602–4606diﬀerence is the apparent instability of R406WS2A in neurons
in contrast to its abundant accumulation in the retina. This
suggests tissue or cell type-speciﬁc diﬀerences in distribution,
abundance or activity of proteases that target Tau. Such
proteases may be particularly sensitive to Tau unphosphory-
lated at sites such as S262, perhaps in combination with
S202/T205 occupation leading to eﬃcient degradation of
R406WS2A in neurons.
Since Tau is processed cell-speciﬁcally, ectopic expression of
kinases and phosphatases that target it [1,2,9] may enhance or
suppress phenotypes of co-expressed Tau non-speciﬁcally and
yield similar degenerative phenotypes. In fact, co-expression of
GSK3b with R406W in R7 photoreceptors, where we cannot
detect the kinase, enhanced degeneration and resulted in the
formation of NFT-like inclusions [12]. Therefore, the conse-
quences of WT and mutant Tau accumulation and their inter-
acting proteins must be carefully considered in light of the
tissue speciﬁc eﬀects described herein. On the other hand, the
cell type-speciﬁc processing of Tau may be capitalized upon
to model the distinct cell type sensitivities, pathologies and
cognitive eﬀects of diﬀerent tauopathies in Drosophila.
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